

Returns

As at 28 February 2026	1m %	3m %	1y %	3y % pa	5y % pa	Since inception % pa (Nov 13)
Gross	-2.4	-7.9	-2.4	0.4	-2.0	10.4
Net of Fees	-2.4	-7.9	-2.4	0.4	-2.0	9.6
S&P Biotechnology Select Industry Index (converted to AUD)	0.7	-4.4	25.6	12.9	-0.8	10.0

Portfolio Composition

NAV per share	% in cash	% shares in USD	% shares in AUD
1.63*	13	64	23

Commentary

February was reporting season for most of our holdings. Most companies have released preliminary results in early January during the JPM conference, so there were few surprises. The month was dominated by discussions around how and when AI will affect software companies. Stocks of SaaS companies were sold off. In the CE portfolio, Veeva Systems (VEEV) was similarly affected, dropping nearly 40% from its recent all time highs before recovering slightly towards the end of the month.

In early February, tariff issues impacted two of our medtech holdings, namely Boston Scientific (BSX) and Terumo, with both stocks dropping nearly 30%, overshadowing good business results achieved during the quarter.

Bioprocessing continues to perform well, with funding returning to the sector and the end of destocking by customers. Tools, genomics and drug discovery continue to be flat as the R&D market in the US is still working through the effects of admin policies, together with continued controversies and changes at the FDA.

At the time of writing, global markets are digesting the consequences of US/Israel actions in Iran and the fallout in the Middle East and Gulf States. The life sciences and healthcare sectors are defensive but not completely immune from serious fallout in the region.

Thank you for your continued trust and confidence in us.

Regards

Peter Phan

Portfolio Manager

Appendix 1: Gross Monthly Returns

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	SPSIBI
2022	-5.5	0	0.5	-4.5	1.0	-0.5	2.0	-1.0	-5.0	2.0	4.0	-0.5	-7.5	-20.4
2023	2.0	2.0	-1.2	1.8	-2.3	0.0	5.4	-5.7	-3.0	-7.5	6.1	6.4	2.9	6.9
2024	1.2	1.0	0.5	-7	2.5	-1.8	0.0	3.1	0.0	-3.5	2.5	1.2	-1.2	10.6
2025	4.8	-2.5	-6.6	2.5	2.0	1.0	1.8	-3.0	7.4	4.6	-2.7	-4.9	2.4	26.0
2026	-0.5	-2.4											-3.0	-1.5

SPSIBI = S&P Biotechnology Select Industry Index (converted to AUD)

Appendix 2: Portfolio Composition

Functional Sub-Sectors*	% of portfolio
Cash	13.0%
Software/Data	19.5%
Tools and Devices	21.0%
Bioprocessing	24.0%
Genomics	4.0%
Radiopharma	10.0%
Drug Discovery	4.0%
Legacy- Financial Industry	7.5%

Industry Sectors*	% of portfolio
Cash	13.0%
Life Sciences	41.0%
Healthcare	38.5%
Legacy- Financial Industry	7.5%

Business Model Categories*	% of portfolio
Cash	13.0%
Picks and Shovels	68.5%
Services	11.0%
Infrastructure	0.0%
Legacy- Financial Industry	7.5%

Appendix 3: CE NAV

CE commenced on 1 November 2013 with shares issued at \$1 per share, backed by \$1 of cash per share.

CE NAV is after payment of dividend and director fees in calendar month February of each year. These payments "reset" the NAV as follows:

- (a) 1.52 to 1.34 in Feb 2017
- (b) 1.46 to 1.39 in Feb 2018
- (c) 1.39 to 1.39 in Feb 2019
- (d) 2.29 to 2.10 in Feb 2020
- (e) 2.53 to 2.25 in Feb 2021
- (f) 2.03 to 1.77 in Feb 2022
- (g) 1.77 to 1.65 in Feb 2023
- (h) 1.65 to 1.65 in Feb 2024
- (i) 1.72 to 1.72 in Feb 2025